-
1h 1m 11s
-
59m 8sPart 4 Session 2: LDL-C
-
40m 52sPart 5 Session 3: Lp(a)
-
1m 15sPart 7 Summary and Close
Watch the on-demand version of New Horizons in Dyslipidaemia (NHD) 2026, a virtual educational event designed for healthcare professionals involved in the management of cardiovascular risk and other lipid-related conditions.
The programme is led by course directors Dr Peter Libby (Brigham and Women’s Hospital, Boston, US), Prof Kausik Ray (Imperial College London, London, UK) and Prof Erik Stroes (Academic Medical Centre, Amsterdam, NL). Through expert-led sessions, explore the rapidly evolving landscape of lipid management, highlighting the persistent gaps between perceived and actual cardiovascular risk, as well as the ongoing underutilisation of effective therapies. Gain valuable insights into new and emerging lipid-lowering treatments, the role of lipids and lipoproteins in cardiovascular outcomes, and practical approaches to navigating increasingly complex clinical guidelines and treatment pathways.
Stay at the forefront of dyslipidaemia management and enhance your clinical practice with the latest expert insights.
You can also catch up on the symposium Severe Hypertriglyceridaemia: Defining the Disease and Its Management here.
*Please note, the live version of New Horizons in Dyslipidaemia was accredited. This on-demand version is not.
Key Learning Objectives
- Gain expert insight on emerging concepts in lipid biology including inflammation and residual risk
- Interpret emerging clinical data across lipid-lowering drug classes
- Review recent guideline updates and their impact on daily practice
- Understand the future landscape in terms of clinical needs and emerging treatment in lipid management primary care
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Lipid Specialists
- Primary Care
- Endocrinologists
More from this programme
Part 1
Welcome and Introduction
In this short welcome, course director Peter Libby outlines the key themes and educational objectives of the programme.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Keynote: Lipids in CVD: From Pathogenesis to Plaque Modulation in Patients
Peter Libby provides an overview to set the stage for the deep-dive topics that follow. He provides insight in to how advances in lipid management are improving patient outcomes.
Part 3
Session 1: Triglycerides and Remnant Particles
This session reviews the clinical impact of elevated triglycerides across the risk spectrum. Faculty discuss the causes and management of severe hypertriglyceridemia to reduce pancreatitis risk and examine the role of mild-to-moderate HTG in remnant cholesterol and residual CV risk. Following this, they review the current TG-lowering therapies and highlight emerging treatment strategies.
Part 4
Session 2: LDL-C
This session focuses on advancing LDL-C management to further reduce cardiovascular risk. Faculty review strategies for targeting the LDL-cholesterol pathway and discuss real-world insights on achieving LDL-C goals in clinical practice. The session also explores emerging therapies, including CETP inhibition and next-generation LDL-lowering approaches.
| 1 session | |
| Session 2: LDL-C | Watch now |
Part 5
Session 3: Lp(a)
This session examines the role of Lp(a) in cardiovascular risk. Faculty review the biology of Lp(a), how it contributes to atherosclerosis and thrombosis, and why it represents an important residual risk factor. The session also evaluates the effects of current lipid-lowering therapies on Lp(a) levels and highlights emerging, targeted treatments designed to improve cardiovascular outcomes.
| 1 session | |
| Session 3: Lp(a) | Watch now |
Part 6
Session 4: Implementing Lipid Management: What Are the Practical Challenges?
This final session addresses the real-world challenges of translating lipid science into everyday practice. Faculty discuss strategies for personalised prevention and how lipid-lowering therapies influence plaque biology and reduce the likelihood of clinical events.
Part 7
Summary and Close
Course director Peter Libby provides a short summary of the day and closes this event.
| 1 session | |
| Summary and Close | Watch now |
Faculty Biographies
Peter Libby
Dr Peter Libby is the Mallinckrodt Professor of Medicine at Harvard Medical School and is the previous Chief of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, Massachusetts.
His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis.
Comments